In the case of KBP-089, a dual amylin and CTR agonist, the additivity of DACRAs and GLP-1 RA in improved insulin sensitivity and body weight reduction was demonstrated in the ratanimal model [119, 120]
Moving forward, we can expect that future research on DPP-4 inhibitors and GLP-1 receptor agonists will continue to expand their application beyond the maintenance of glycemic control in patients with type 2 diabetes
Toxicology and Safety Studies: Thoroughly evaluating the toxicity profile of the combination in animal models, looking for any adverse effects on organs or physiological systems that are not seen with individual peptides
Hims Weight Loss Key Features- Are They Effective
The most common adverse effects are gastrointestinal in nature including nausea, vomiting, diarrhea, and constipationwhich can lead to dehydration if not properly managed
These observations remain within controlled research environments and represent experimental findings, not therapeutic claims or clinical outcomes